<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1511222902
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        METOJECT 50 mg/ml solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METHOTREXATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        105.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ONCOTEC PHARMA PRODUCTION GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ONCOTEC PHARMA PRODUCTION GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            medac Gesellschaft für klinische Spezialpräparate mbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Metoject contains methotrexate as active substance.<br />Methotrexate is a substance with the following properties:<br />&bull; it interferes with the growth of certain cells in the body that reproduce quickly<br />&bull; it reduces the activity of the immune system (the body&rsquo;s own defence mechanism)<br />&bull; it has anti-inflammatory effects<br />Metoject is indicated for the treatment of<br /> active rheumatoid arthritis in adult patients.<br /> polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to<br />nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,<br /> severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms<br />of therapy such as phototherapy, PUVA, and retinoids, and severe psoriatic arthritis in<br />adult patients.<br /> mild to moderate Crohn&rsquo;s disease in adult patients when adequate treatment with other<br />medicines is not possible.<br />Rheumatoid arthritis (RA) is a chronic collagen disease, characterised by inflammation of the<br />synovial membranes (joint membranes). These membranes produce a fluid which acts as a&nbsp;lubricant for many joints. The inflammation causes thickening of the membrane and swelling of<br />the joint.<br />Juvenile arthritis concerns children and adolescents less than 16 years. Polyarthritic forms are<br />indicated if 5 or more joints are affected within the first 6 months of the disease.<br />Psoriatic arthritis is a kind of arthritis with psoriatric lesions of the skin and nails, especially at<br />the joints of fingers and toes.<br />Psoriasis is a common chronic skin disease, characterised by red patches covered by thick, dry,<br />silvery, adherent scales.<br />Metoject modifies and slows down the progression of the disease.<br />Crohn&rsquo;s disease is a type of inflammatory bowel disease that may affect any part of the<br />gastrointestinal tract causing symptoms such as abdominal pain, diarrhoea, vomiting or weight<br />loss.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Metoject if you<br />&bull; are allergic to methotrexate or any of the other ingredients of this medicine (listed in<br />section 6),<br />&bull; suffer from severe liver or kidney diseases or blood diseases.<br />&bull; regularly drink large amounts of alcohol.<br />&bull; suffer from a severe infection, e.g. tuberculosis, HIV or other immunodeficiency<br />syndromes.<br />&bull; suffer from ulcers in the mouth, stomach ulcer or intestinal ulcer.<br />&bull; are pregnant or breast-feeding (see section &ldquo;Pregnancy, breast-feeding and fertility&rdquo;).<br />&bull; receive vaccinations with live vaccines at the same time.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Metoject if:<br />&bull; you are elderly or if you feel generally unwell and weak.<br />&bull; your liver function is impaired.<br />&bull; you suffer from dehydration (water loss).<br />Special precautionary measures for treatment with Metoject<br />Methotrexate temporarily affects sperm and egg production, which is reversible in most cases.<br />Methotrexate can cause miscarriage and severe birth defects. You must avoid becoming pregnant<br />when using methotrexate and for at least six months after treatment has stopped. See also section<br />&ldquo;Pregnancy, breast-feeding and fertility&rdquo;.<br />Recommended follow-up examinations and safety measures:<br />Even when Metoject is administered in low doses, severe side effects can occur. In order to<br />detect them in time, check-ups and laboratory tests have to be carried out by your doctor.</p><p>Before therapy:<br />Before starting the treatment, blood samples will be taken in order to check that you have enough<br />blood cells, tests to check your liver function, serum albumin (a protein in the blood) and kidney<br />function. Your doctor will also check if you suffer from tuberculosis (infectious disease in<br />combination with little nodules in the affected tissue) and a chest X-ray will be taken.<br />During therapy:<br />You will have the following tests at least once a month during the first six months and at least<br />every three months thereafter:<br />&bull; Examination of the mouth and throat for alterations of the mucosa<br />&bull; Blood tests<br />&bull; Check of liver function<br />&bull; Check of kidney function<br />&bull; Check of respiratory system and if necessary lung function test<br />Acute bleeding from the lungs in patients with underlying rheumatologic disease has been<br />reported with methotrexate. If you experience symptoms of spitting or coughing up blood you<br />should contact your doctor immediately.<br />Methotrexate may affect your immune system and vaccination results. It may also affect the<br />result of immunological tests. Inactive, chronic infections (e.g. herpes zoster [shingles],<br />tuberculosis, hepatitis B or C) may flare up. During therapy with Metoject you must not be<br />vaccinated with live vaccines.<br />Radiation induced dermatitis and sun-burn can reappear under methotrexate therapy (recallreaction).<br />Psoriatic lesions can exacerbate during UV-irradiation and simultaneous<br />administration of methotrexate.<br />Enlarged lymph nodes (lymphoma) may occur and therapy must then be stopped.<br />Diarrhoea can be a toxic effect of Metoject and requires an interruption of therapy. If you suffer<br />from diarrhoea please speak to your doctor.<br />Certain brain disorders (encephalopathy/leukoencephalopathy) have been reported in cancer<br />patients receiving methotrexate.Such side effects cannot be excluded when methotrexate is used<br />to treat other diseases.<br />Other medicines and Metoject<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines. Please note that this also applies to medicines that you will take in the future.<br />The effect of the treatment may be affected if Metoject is administered at the same time as<br />certain other medicines:<br />&bull; Antibiotics such as: tetracyclines, chloramphenicol, and non-absorbable broad-spectrum<br />antibiotics, penicillines, glycopeptides, sulphonamides ciprofloxacin and cefalotin<br />(medicines to prevent/fight certain infections)&nbsp;&bull; Non-steroidal anti-inflammatory drugs or salicylates (medicines against pain and/or<br />inflammation such as acetylsalicylic acid, diclofenac and ibuprofen or pyrazole)<br />&bull; Probenecid (medicine against gout)<br />&bull; Weak organic acids like loop diuretics (&ldquo;water tablets&rdquo;)<br />&bull; Medicines, which may have adverse effects on the bone marrow, e.g. trimethoprimsulphamethoxazole<br />(an antibiotic) and pyrimethamine<br />&bull; Other medicines used to treat rheumatoid arthritis such as leflunomide, sulphasalazine<br />and azathioprine.<br />&bull;<br />&bull; Mercaptopurine (a cytostatic agent)<br />&bull; Retinoids (medicine against psoriasis and other dermatological diseases)<br />&bull; Theophylline (medicine against bronchial asthma and other lung diseases)<br />&bull; Some medicines against stomach trouble such as omeprazole and pantoprazole.<br />&bull; Hypoglycaemics (medicines that are used to lower the blood sugar)<br />Vitamins containing folic acid may impair the effect of your treatment and should only be taken<br />when advised by your doctor.<br />Vaccination with live vaccine must be avoided.<br />Metoject with food, drink and alcohol<br />Alcohol as well as large amounts of coffee, caffeine-containing soft drinks and black tea should<br />be avoided during treatment with Metoject.<br />Pregnancy, breast-feeding and fertility<br />Pregnancy<br />Do not use Metoject during pregnancy or if you are trying to become pregnant. Methotrexate can<br />cause birth defects, harm the unborn child or cause miscarriage. It is associated with<br />malformations of the skull, face, heart and blood vessels, brain and limbs. Therefore, it is very<br />important that methotrexate is not given to pregnant patients or patients planning to become<br />pregnant.<br />In women of child-bearing age, any possibility of pregnancy must be excluded with appropriate<br />measures, e.g. pregnancy test, before starting treatment.<br />You must avoid becoming pregnant whilst taking methotrexate and for at least 6 months after<br />treatment is stopped by using reliable contraception throughout this time (see also section<br />&ldquo;Warnings and precautions&rdquo;).<br />If you do become pregnant during treatment or suspect you might be pregnant, speak to your<br />doctor as soon as possible. You should be offered advice regarding the risk of harmful effects on<br />the child through treatment. If you wish to become pregnant you should consult your doctor,<br />who may refer you for specialist advice before the planned start of treatment.<br />Breast-feeding<br />Stop breast-feeding prior to and during treatment with Metoject.&nbsp;</p><p>Male fertility<br />The available evidence does not indicate an increased risk of malformations or miscarriage if the<br />father takes methotrexate less than 30 mg/week. However, a risk cannot be completely excluded.<br />Methotrexate may be genotoxic. This means that the medicine may cause genetic mutation.<br />Methotrexate can affect sperm production with the potential to cause birth defects. Therefore,<br />you should avoid fathering a child or to donate semen whilst taking methotrexate and for at least<br />6 months after treatment is stopped.<br />Driving and using machines<br />Treatment with Metoject may cause adverse reactions affecting the central nervous system, e.g.<br />tiredness and dizziness. Thus the ability to drive a vehicle and/or to operate machines may, in<br />certain cases, be compromised. If you feel tired or drowsy you should not drive or use machines.<br />Important information about some of the ingredients of Metoject<br />This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially<br />&ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Important warning about the dose of Metoject (methotrexate):<br />Use Metoject only once a week for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis,<br />psoriasis and psoriatic arthritis, and Crohn&rsquo;s disease. Using too much of Metoject (methotrexate) may be<br />fatal. Please read section 3 of this leaflet very carefully. If you have any questions, please talk to your<br />doctor or pharmacist before you take this medicine.<br />Always use this medicine exactly as your doctor has told you. Check with your doctor or<br />pharmacist if you are not sure.<br />Your doctor decides on the dose, which is adjusted individually. Usually it takes 4 &ndash; 8 weeks<br />before there is any effect of the treatment.<br />Metoject is administered by or under the supervision of a physician or healthcare staff as an<br />injection under the skin (subcutaneous injection) once a week only. Together with your doctor<br />you decide on a suitable weekday each week on which you receive your injection.<br />Use in children and adolescents<br />The doctor decides on the appropriate dose in children and adolescents with polyarthritic forms<br />of juvenile idiopathic arthritis. The use in children and adolescents is also by subcutaneous<br />injection. Metoject is not recommended in children less than 3 years of age due to insufficient<br />experience in this age group.<br />Method and duration of administration<br />Metoject is injected subcutaneously once weekly!<br />The duration of the treatment is determined by the treating physician. Treatment of rheumatoid<br />arthritis, juvenile idiopathic arthritis, psoriasis vulgaris,and psoriatic arthritis with Metoject is a<br />long-term treatment.&nbsp;At the start of your treatment, Metoject may be injected by medical staff. However, your doctor<br />may decide that you can learn how to inject Metoject under the skin yourself. You will receive<br />appropriate training for you to do this.<br />Under no circumstances should you attempt to inject yourself, unlessyou have been<br />trained to do so.<br />Please refer to the instructions for use at the end of the leaflet.<br />The manner of handling and disposal must be consistent with that of other cytostatic preparations<br />in accordance with local requirements. Pregnant health care personnel should not handle and/or<br />administer Metoject.<br />Methotrexate should not come into contact with the surface of the skin or mucosa. In the event of<br />contamination, the affected area must be rinsed immediately with plenty of water.<br />If you use more Metoject than you should<br />If you use more Metoject than you should, talk to your doctor immediately.<br />If you forget to use Metoject<br />Do not take a double dose to make up for a forgotten dose.<br />If you stop using Metoject<br />If you stop using Metoject, talk to your doctor immediately.<br />If you have the impression that the effect of Metoject is too strong or too weak, you should talk<br />to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />The frequency as well as the degree of severity of the side effects depends on the dosage level<br />and the frequency of administration. As severe side effects may occur even at low dosage, it is<br />important that you are monitored regularly by your doctor. Your doctor will do tests to check<br />for abnormalities developing in the blood (such as low white blood cells, low platelets,<br />lymphoma) and changes in the kidneys and the liver.<br />Tell your doctor immediately if you experience any of the following symptoms, as these may<br />indicate a serious, potentially life-threatening side effect, which require urgent specific<br />treatment:<br /> persistent dry, non-productive cough, shortness of breath and fever; these may be<br />signs of an inflammation of the lungs [common]<br /> spitting or coughing blood; these might be signs of bleeding from the lungs [not known]<br /> symptoms of liver damage such as yellowing of the skin and whites of the eyes;<br />methotrexate can cause chronic liver damage (liver cirrhosis), formation of scar tissue of&nbsp;the liver (liver fibrosis), fatty degeneration of the liver [all uncommon], inflammation of<br />the liver (acute hepatitis) [rare] and liver failure [very rare]<br /> allergy symptoms such as skin rash including red itchy skin, swelling of the hands,<br />feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or<br />breathing) and feeling you are going to faint; these may be signs of severe allergic<br />reactions or an anaphylactic shock [rare]<br /> symptoms of kidney damage such as swelling of the hands, ankles or feet or changes<br />in frequency of urination or decrease (oliguria) or absence of urine (anuria); these<br />may be signs of kidney failure [rare]<br /> symptoms of infections, e.g. fever, chills, achiness, sore throat; methotrexate can make<br />you more susceptible to infections. Severe infections like a certain type of pneumonia<br />(Pneumocystis jirovecii pneumonia) or blood poisoning (sepsis) may occur [rare]<br /> symptoms such as weakness of one side of the body (stroke) or pain, swelling,<br />redness and unusual warmth in one of your legs (deep vein thrombosis); This may<br />happen when a dislodged blood clot causes a blockage of a blood vessel<br />(thromboembolic event) [rare]<br /> fever and serious deterioration of your general condition, or sudden fever<br />accompanied by a sore throat or mouth, or urinary problems; methotrexate can cause<br />a sharp fall in white blood cells (agranulocytosis) and severe bone marrow suppression<br />[very rare]<br /> unexpected bleeding, e.g. bleeding gums, blood in the urine, vomiting blood or<br />bruising, these can be signs of a severely reduced number of blood platelets caused by<br />severe courses of bone marrow depression [very rare]<br /> symptoms such as severe headache often in combination with fever, neck stiffness,<br />feeling sick, vomiting, disorientation and sensitivity to light may indicate an<br />inflammation of the membranes of the brain (acute aseptic meningitis) [very rare]<br /> certain brain disorders (encephalopathy/leukoencephalopathy) have been reported in<br />cancer patients receiving methotrexate. Such side effects cannot be excluded when<br />methotrexate therapy is used to treat other diseases. Signs of this kind of brain disorders<br />may be altered mental state, movement disorders (ataxia), visual disturbances or<br />disturbances of memory [not known]<br /> severe skin rash or blistering of the skin (this can also affect your mouth, eyes and<br />genitals); these may be signs of the conditions called Stevens Johnson syndrome or<br />burned skin syndrome (toxic epidermal necrolysis) [very rare]<br />In the following, please find the other side effects that may occur:<br />Very common: may affect more than 1 in 10 people<br />&bull; Inflammation of the mouth lining, indigestion, feeling sick, loss of appetite, abdominal<br />pain<br />&bull; Abnormal liver function test (ASAT, ALAT, bilirubin, alkaline phosphatase)<br />Common: may affect up to 1 in 10 people<br />&bull; Mouth ulcers, diarrhoea<br />&bull; Rash, reddening of the skin, itching<br />&bull; Headache, tiredness, drowsiness<br />&bull; Reduced blood cell formation with decrease in white and/or red blood cells and/or platelets</p><p>Uncommon: may affect up to 1 in 100 people<br />&bull; Throat inflammation.<br />&bull; Inflammation of the bowels, vomiting, inflammation of pancreas, black or tarry stools,<br />gastrointestinal ulcers and bleeding<br />&bull; Increased sensitivity to light, loss of hair, increased number of rheumatic nodules, skin<br />ulcers, shingles, inflammation of blood vessels, herpes-like skin rash, hives<br />&bull; Onset of diabetes mellitus<br />&bull; Dizziness, confusion, depression<br />&bull; Decrease in serum albumin<br />&bull; Decrease in the number of all blood cells and platelets<br />&bull; Inflammation and ulcer of the urinary bladder or vagina, reduced kidney function,<br />disturbed urination<br />&bull; Joint pain, muscle pain, reduction of bone mass<br />Rare: may affect up to 1 in 1,000 people<br />&bull; Inflammation of gum tissue<br />&bull; Increased skin pigmentation, acne, blue spots on the skin due to vessel bleeding<br />(ecchymosis, petechiae), allergic inflammation of blood vessels<br />&bull; Decreased number of anti-bodies in the blood<br />&bull; Infection (incl. reactivation of inactive chronic infection), red eyes (conjunctivitis)<br />&bull; Mood swings (mood alterations)<br />&bull; Visual disturbances<br />&bull; Inflammation of the sac around the heart, accumulation of fluid in the sac around the heart,<br />obstruction of cardiac filling due to fluid in the sac around the heart<br />&bull; Low blood pressure<br />&bull; Formation of scar tissue in the lung (pulmonary fibrosis), shortness of breath and<br />bronchial asthma, accumulation of fluid in the sac around the lung<br />&bull; Stress fracture<br />&bull; Electrolyte disturbances<br />&bull; Fever, wound-healing impairment<br />Very rare: may affect up to 1 in 10,000 people<br />&bull; Acute toxic dilatation of the gut (toxic megacolon)<br />&bull; Increased pigmentation of the nails, inflammation of the cuticles (acute paronychia), deep<br />infection of hair follicles (furunculosis), visible enlargement of small blood vessels<br />&bull; Pain, loss of strength or sensation of numbness or tingling / having less sensitivity to<br />stimulation than normal, changes in taste (metallic taste), convulsions, paralysis,<br />meningism<br />&bull; Impaired vision, non-inflammatory eye disorder (retinopathy)<br />&bull; Loss of sexual drive, impotence, male breast enlargement, defective sperm formation<br />(oligospermia), menstrual disorder, vaginal discharge<br />&bull; Enlargement of lymphatic nodes (lymphoma)<br />&bull; Lymphoproliferative disorders (excessive growth of white blood cells)<br />Not known: frequency cannot be estimated from the available data:<br />&bull; Increased number of certain white blood cells.</p><p>&bull; Nosebleed.<br />&bull; Proteins in urine.<br />&bull; Feeling of weakness.<br />&bull; Bone damage in the jaw (secondary to excessive growth of white blood cells).<br />&bull; Tissue destruction at injection site.<br />&bull; Redness and shedding of skin<br />&bull; Swelling<br />Subcutaneous application of methotrexate is locally well tolerated. Only mild local skin reactions<br />were observed, decreasing during therapy.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side<br />effects not listed in this leaflet. You can also report side effects directly via (see details below).<br />By reporting side effects you can help provide more information on the safety of this medicine.<br />The National Pharmacovigilance &amp; Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Store below 25 &deg;C.<br />Keep the pre-filled syringes in the outer carton in order to protect from light.<br />Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to<br />the last day of that month.<br />Medicines should not be disposed via wastewater or household waste. Ask your pharmacist how<br />to dispose of medicines no longer required. The measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Metoject contains<br />&bull; The active substance is methotrexate. 1 ml of solution contains methotrexate disodium<br />corresponding to 50 mg methotrexate.<br />&bull; The other ingredients are sodium chloride, sodium hydroxide, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Metoject looks like and contents of the pack
Metoject pre-filled syringes contain a clear, yellow-brown solution.
The following pack sizes are available:
Pre-filled syringes with embedded sc. injection needles and graduation containing 0.20 ml,
0.30 ml, 0.40 ml, 0.50 ml and 0.60 ml solution for injection in packs of 1 pre-filled syringe.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and batch releaser<br />medac Gesellschaft f&uuml;r klinische Spezialpr&auml;parate mbH<br />Theaterstr. 6<br />22880 Wedel<br />Germany<br />Phone: +49 4103 8006-0<br />Fax: +49 4103 8006-100<br />Manufacturer of the drug product and quality control/testing:<br />Oncotec Pharma Produktion GmbH<br />Am Pharmapark<br />06861 Dessau-Ro&szlig;lau<br />Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یحتوي میتوجیكت على المیثوتریكسیت كمادة فعالة.<br />میثوتریكسیت مادة تتمتع بالخصائص التالیة:<br />&bull; تتداخل مع نمو خلایا معینة في الجسم والتي تتكاثر بسرعة.<br />&bull; تقلل من نشاط الجھاز المناعى (آلیة دفاع الجسم عن نفسھ).<br />&bull; لھا خصائص مضادة للالتھابات.<br />یستخدم میتوجیكت لعلاج ما یلي<br />&bull; التھاب المفاصل الروماتیزمي النشط في المرضى البالغین.<br />&bull; أشكال التھاب المفاصل المتعدد الحاد والنشط مجھول السبب لدى الیافعین وذلك عندما تكون الإستجابة لمضادات<br />الالتھاب الغیر ستیرویدیة غیر كافیة.<br />&bull; الصدفیة الشدیدة والعنیدة المسببة للإعاقة والتي لم تستجیب لأنواع العلاج الأخرى مثل العلاج الضوئي والعلاج<br />أو الریتینویدات، والتھاب المفاصل الصدفي لدى البالغین. PUVA بالأشعة فوق البنفسجیة<br />في المرضى البالغین عندما یكون العلاج (Crohn&rsquo;s Disease) &bull; الاصابة الخفیفة الى المعتدلة بمرضكرون<br />المناسب مع أدویة أخرى غیر ممكن .<br />مرض التھاب المفاصل الروماتیزمي ھو مرض مزمن في الكولاجین من أعراضھ التھاب الأغشیة الزلیلیة (أغشیة<br />المفاصل). وتفرز ھذه الأغشیة سائلا یعمل عمل التشحیم للعدید من المفاصل. ویسبب الالتھاب زیادة في لزوجة ھذا السائل<br />وتورم المفصل.</p><p>التھاب مفاصل الیافعین والذي یصیب الأطفال والمراھقین دون السادسة عشرة من العمر. یتم وصف الحالة بالتھاب<br />المفصل المتعدد إذا أصیبت ٥ مفاصل أو أكثر بالالتھاب خلال الستة أشھر الأولى من بدایة المرض.<br />التھاب المفاصل الصدفي ھو نوع من التھاب المفاصل یتمیز بوجود قرح صدفیة على البشرة وعلى الأظافر وخاصة في<br />مفاصل أصابع الیدین والقدمین .<br />الصدفیة ھي مرض جلدي مزمن وشائع یتمیز بوجود بقع حمراء مغطاة بخلایا سمیكة وجافة وفضیة اللون تشبھ الصدف.<br />یقوم میتوجیكت بتعدیل وإبطاء تطور المرض.<br />مرضكرون ھو نوع من أمراضالتھاب الأمعاء التي قد تؤثر على أي جزء من الجھاز الھضمي ویسبب أعراضمثل<br />آلام البطن والإسھال والتقیؤ أو فقدان الوزن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم میتوجیكت إذا كنت:<br />.( &bull; تعانى من الحساسیة للمیثوتریكسیت أو لأي من المكونات الأخرى لھذا الدواء (المذكورة في القسم ٦<br />&bull; تعاني من اعتلال شدید بالكبد أو الكلیة أو أمراض الدم.<br />&bull; تستھلك كمیات كبیرة من الكحول بانتظام.<br />&bull; تعاني من عدوى شدیدة مثل السل أو مرض نقص المناعة (الإیدز) أو أي من أعراض نقص المناعة الأخرى.<br />&bull; تعاني من تقرحات في الفم، قرحة في المعدة أو قرحة في الأمعاء.<br />&bull; حامل أو مرضع (بالنسبة للسیدات)(انظر قسم &quot;الحمل والإرضاع والخصوبة.&quot;)<br />&bull; تتناول أمصالاً بھا مصل حي في نفس الوقت أثناء العلاج بمیتوجیكت.<br />التحذیرات والإحتیاطات<br />تحدث إلى طبیبك أو الصیدلي قبل استعمال میتوجیكت إذا:<br />&bull; كنت كبیرا في السن أو إذا كنت تشعر بالاعیاء أو الضعف العام.<br />&bull; كنت تعاني من اعتلال في وظائف الكبد.<br />&bull; كنت تعاني من الجفاف (نقص المیاه بالجسم).<br />إجراءات احترازیة خاصة للعلاج بمیتوجیكت<br />یؤثر المیثوتریكسات مؤقتًا على إنتاج الحیوانات المنویة والبویضات ، وھو أمر یمكن عكسھ في معظم<br />الحالات .یمكن أن یسبب المیثوتریكسات الإجھاض والعیوب الخلقیة الشدیدة .یجب علیك تجنب الحمل عند<br />استخدام المیثوتریكسات ولمدة ستة أشھر على الأقل بعد توقف العلاج .انظر أیضًا قسم &quot;الحمل والإرضاع<br />والخصوبة.&quot;<br />مراجعات وفحوصات وإجراءات السلامة التي یوصى بھا:<br />على الرغم من إعطاء میتوجیكت بجرعات منخفضة إلا أنھ من الممكن حدوث آثار جانبیة شدیدة، ولكى یتم الكشف عن<br />حدوث ھذه الآثار الجانبیة یتعین إجراء فحوصات مخبریة وفحص للمریض بواسطة الطبیب.<br />قبل بدء المعالجة:</p><p>قبل بدء المعالجة یتم أخذ عینات من الدم للتأكد من وجود خلایا دم كافیة وكذلك لفحص وظائف الكبد ونسبة الألبومین (نوع<br />من البروتینات الموجودة في الدم) ووظائف الكلى.<br />كذلك سیفحص طبیبك إذا ما كنت تعاني من مرض السل (وھو مرض معدي بالاضافة إلى وجود عقد صغیرة في منطقة<br />العدوى بالصدر) ویقوم باجراء أشعة إكس على الصدر.<br />أثناء المعالجة:<br />سوف تقوم باجراء الفحوصات التالیة على الأقل مرة كل شھر خلال الستة أشھر الأولى و مرة كل ثلاثة أشھر بعد ذلك:<br />&bull; فحص الفم والحلق لإكتشاف أي تغییرات في الغشاء المخاطي.<br />&bull; تحلیل الدم.<br />&bull; فحص وظائف الكبد.<br />&bull; فحص وظائف الكلى.<br />&bull; فحص الجھاز التنفسي و إذا إحتاج الأمر یتم إجراء اختبار لوظیفة الرئة.<br />تم الإبلاغ عن نزیف الرئتین الحاد في المرضى الذین یعانون من أمراضالروماتیزم الأساسیة باستخدام المیثوتریكسات .<br />إذا كنت تعاني من أعراضبصق أو سعال الدم ، یجب علیك الاتصال بطبیبك على الفور.<br />قد یؤثر المیثوتریكسیت على الجھاز المناعي وعلى نتائج التطعیم باللقاحات، كما یمكن أیضا أن یؤثر على نتیجة<br />الإختبارات المناعیة. ویمكن أن تنشط فجأة بشكل كبیر عدوى مزمنة غیر فعالة (مثل الھربس النطاقي (شنجلز)، السل،<br />الالتھاب الكبدي بفیروس بي أو سي). كما یجب ألا تعطى أي لقاحات حیة خلال فترة المعالجة بمیتوجیكت.<br />الالتھابات الجلدیة التي یسببھا الإشعاع أو حروق أشعة الشمس یمكن أن تعود للظھور أثناء المعالجة بمیثوتریكسیت<br />(تفاعل إسترجاعي). كما یمكن أن تتفاقم قرح الصدفیة أثناء التعرض للأشعة فوق البنفسجیة بالتزامن مع استعمال<br />المیثوتریكسیت.<br />قد یحدث تضخم في الغدد اللیمفاویة (لیمفوما) وحین ذلك یجب إیقاف العلاج.<br />الإسھال من الممكن أن یكون تأثیرا ساما لمیتوجیكت ویتطلب إیقاف العلاج، فإذا كنت تعاني من الإسھال الرجاء التحدث<br />مع طبیبك.<br />قد تم الابلاغ عن حدوث الاعتلال الدماغي (اضطراب الدماغ / اعتلال بیضاء الدماغ) لدى مرضى السرطان الذین یتلقون<br />العلاج بالمیثوتریكسات.<br />لا یمكن استبعاد ھذا التأثیر الجانبي عند استخدام المیثوتریكسات لعلاج أمراض أخرى.<br />الأدویة الأخرى ومیتوجیكت:<br />یرجى إخبار الطبیب أو الصیدلي إذا كنت تستعمل أو إستعملت مؤخرا أو ربما ستستعمل أي أدویة أخرى. یرجى ملاحظة<br />أن ھذا ینطبق أیضًا على الأدویة التي ستتناولھا في المستقبل.<br />إن مفعول العلاج قد یتأثر إذا أعطي میتوجیكت بالتزامن مع أدویة معینة أخرى مثل:<br />&bull; المضادات الحیویة مثل: التتراسیكلینات، الكلورامفینیكول، والمضادات الحیویة الواسعة المجال الغیر قابلة<br />للإمتصاص، والبنسیلینات، والجلیكوبیبتایدات، السالفونامایدات ، سیبروفلوكساسین، سیفالوتین (الأدویة التي تمنع أو<br />تقاوم أنواع معینة من العدوى).<br />&bull; مضادات الالتھاب الغیر ستیرودیة أو السالیسایلات (أدویة مضادة للألم أو الإلتھاب أو كلیھما مثل حمضالأسیتیل<br />سالیسیلیك، دیكلوفیناك و ایبوبروفین أو البیرازول).</p><p>&bull; بروبنسید (دواء لعلاج النقرس).<br />&bull; الأحماض العضویة الضعیفة مثل مدرات البول الحلقیة (&quot;أقراص مدرة للبول&quot;) .<br />&bull; الأدویة التي لھا تأثیر معاكس على نخاع العظم مثل ترایمیثوبریم - سلفامیثوكسازول (مضاد حیوي) وبایریمیثامین.<br />&bull; أدویة أخرى تستخدم لعلاج التھاب المفاصل الروماتیزمي مثل لفلونومید، سولفاسالازین والأزاثیوبرین.<br />&bull; میركابتوبیورین (عامل مثبط للخلایا).<br />&bull; الریتینویدات (دواء مضاد للصدفیة وأمراض جلدیة أخرى).<br />&bull; ثیوفیللین (دواء للربو الشعبي وأمراض أخرى بالرئة)<br />&bull; بعضالأدویة المضادة لمشاكل المعدة مثل أومیبرازول والبانتوبرازول.<br />&bull; خافضات السكر في الدم (أدویة لتخفیض نسبة السكر في الدم).<br />الفیتامینات التي تحتوي على حمض الفولیك یمكن أن تعیق مفعول الدواء ویجب ألا تؤخذ إلا بعد استشارة الطبیب.<br />یجب تجنب التطعیمات التي تحتوي على تطعیمات حیة.<br />استعمال میتوجیكت مع الطعام والشراب والكحول:<br />الكحول والكمیات الكبیرة من القھوة والمشروبات التي تحتوي على الكافیین والشاي الأسود یجب تجنبھا أثناء المعالجة<br />بمیتوجیكت.<br />الحمل والإرضاع والخصوبة:<br />الحمل<br />لا تستخدمي میتوجیكت أثناء الحمل أو إذا كنتِ تحاولین الحمل .یمكن أن یسبب المیثوتریكسات تشوھات خلقیة أو یؤذي<br />الجنین أو یتسبب في الإجھاض، وھو یصاحب تشوھات في الجمجمة والوجھ والقلب والأوعیة الدمویة والدماغ<br />والأطراف. لذلك ، من المھم جدًا عدم إعطاء المیثوتریكسات للمرضى الحوامل أو المرضى الذین یخططون للحمل.<br />یجب على النساء في سن الحمل التأكد من عدم احتمال الحمل وذلك باستخدام وسائل مناسبة مثل اجراء اختبار الحمل قبل<br />البدء في العلاج.<br />یجب علیكِ تجنب الحمل أثناء تناول المیثوتریكسات ولمدة ٦ أشھر على الأقل بعد التوقف عن العلاج باستخدام وسائل منع<br />الحمل الموثوقة طوال ھذا الوقت (انظر أیضًا قسم &quot;التحذیرات والاحتیاطات&quot;).<br />إذا أصبحتِ حاملا أًثناء العلاج أو تشك في أنك حامل ، فتحدث إلى طبیبك في أقرب وقت ممكن .یجب أن یتم تقدیم<br />المشورة لك بشأن مخاطر الآثار الضارة على الطفل عن طریق العلاج.<br />إذا كنتِ ترغبین في الحمل یجب علیكِ استشارة طبیبك ، الذي قد یحیلك للحصول على مشورة متخصصة قبل البدء<br />المخطط للعلاج.<br />الإرضاع<br />توقفي عن الإرضاع قبل وأثناء العلاج بمیتوجیكت.<br />خصوبة الذكور<br />لا تشیر الأدلة المتاحة إلى زیادة خطر حدوث تشوھات أو إجھاضإذا كان الأب یأخذ المیثوتریكسات أقل من ۳۰ ملغ /<br />أسبوع .ومع ذلك ، لا یمكن استبعاد الخطر تماما .قد یكون المیثوتریكسات سامًا للجینات .ھذا یعني أن الدواء قد یسبب<br />طفرة جینیة .یمكن أن یؤثر المیثوتریكسات على إنتاج الحیوانات المنویة وقد یتسبب في حدوث تشوھات خلقیة .لذلك ،<br />یجب تجنب إنجاب الأطفال أو التبرع بالسائل المنوي أثناء تناول المیثوتریكسات ولمدة ٦ أشھر على الأقل بعد توقف<br />العلاج.<br />قیادة السیارات وتشغیل الآلات</p><p>المعالجة بمیتوجیكت یمكن أن یكون لھا آثار ضارة على الجھاز العصبي المركزي مثل الشعور بالتعب والدوخة، لذلك فإن<br />القدرة على القیادة أوتشغیل الآلات یمكن أن تتأثر في حالات معینة. فإذا شعرت بالتعب أو الدوخة فلا تقدم على قیادة سیارة<br />أو تشغیل آلة .<br />معلومات ھامة حول بعض مكونات میتوجیكت<br />یحتوي ھذا الدواء على أقل من ۱مللیمول من الصودیوم ( ۲۳ مجم) في كل جرعة وذلك یعني أنھ یعتبر خالیا من<br />الصودیوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تحذیر ھام بخصوصجرعة میتوجیكت (میثوتریكسات)<br />استخدم میتوجیكت مرة واحدة فقط في الأسبوع لعلاج التھاب المفاصل الروماتویدي والتھاب المفاصل الشبابي مجھول<br />السبب والصدفیة والتھاب المفاصل الصدفي ومرضكرون .قد یكون استخدام الكثیر من میتوجیكت (میثوتریكسات)<br />قاتلا .الرجاء قراءة القسم ۳ من ھذه النشرة بعنایة فائقة .إذا كانت لدیك أي أسئلة ، یرجى التحدث مع طبیبك أو الصیدلي<br />قبل تناول ھذا الدواء.<br />استخدم ھذا الدواء دائمًا تمامًا كما أخبرك طبیبك .استشر طبیبك أو الصیدلي إذا لم تكن متأكدًا.<br />سوف یقوم طبیبك بتحدید الجرعة لك حیث أنھا تحدد لكل حالة على حده. وعادة لایكون ھناك أي تأثیر للعلاج قبل مضي<br />۸ أسابیع. &ndash; ٤<br />یعطى میتوجیكت بواسطة الطبیب أو أي من أعضاء الھیئة الطبیة عن طریق الحقن تحت الجلد مرة واحدة فقط أسبوعیا.<br />ولك أن تحدد مع طبیبك الیوم المناسب من كل أسبوع كي یتم فیھ حقنك بالدواء.<br />الاستخدم في الأطفال والمراھقین<br />ویقوم الطبیب بتحدید الجرعة المناسبة للأطفال والمراھقین المصابین بأشكال التھاب المفاصل المتعدد للیافعین مجھولة<br />السبب. یتم استخدامھ للأطفال والمراھقین أیضًا عن طریق الحقن تحت الجلد.<br />ولا یوُصى بوصف میتوجیكت للأطفال أقل من ۳ سنوات من العمر نظرا لعدم توافر معلومات كافیة حول وصفھ لھذه الفئة<br />العمریة.<br />طریقة ومدة الاستعمال<br />یعطى میتوجیكت عن طریق الحقن تحت الجلد مرة واحدة أسبوعیا.ً<br />تحدد مدة العلاج بواسطة الطبیب المعالج. ویعتبرعلاج التھاب المفاصل الروماتیزمي والتھاب المفاصل المجھول السبب<br />للیافعین والصدفیة الشائعة والتھاب المفاصل الصدفي علاجا طویل الأمد.<br />في بدایة علاجك، قد یتم حقن میتوجیكت من قبل الطاقم الطبي. ومع ذلكقد یقرر الطبیب أنك یمكنك تعلم كیفیة حقن<br />میتوجیكت تحت الجلد بنفسك. سوفتتلقى التدریب المناسب لك للقیام بذلك. یجب ألا تحاول تحت أي ظرف من الظروف أن<br />تحقن نفسك ، إلا إذا كنت قد تدربت على فعل ذلك.<br />الرجاء الرجوع إلى إرشادات الاستخدام في نھایة ھذه النشرة.<br />طریقة التعامل مع الدواء والتخلص منھ یجب أن تتفق مع المستحضرات الأخرى المثبطة للخلایا طبقا للمتطلبات المحلیة.<br />ویجب على الحوامل من العاملات بالمجال الصحي عدم التعامل مع أو إعطاء میتوجیكت للمرضى.</p><p>یجب ألا یلامس المیثوتریكسیت سطح البشرة أوالغشاء المخاطي، وفي حال حدوث ذلك تغسل المنطقة المصابة بكمیة<br />وفیرة من المیاه.<br />إذا استخدمت میتوجیكت أكثر مما یجب<br />إذا استخدمت میتوجیكت اكثر مما یجب علیك، تحدث إلى الطبیب فورا.<br />إذا نسیت استخدام میتوجیكت<br />لا تأخذ جرعة مضاعفة لتعویضالجرعة المنسیة.<br />إذا قمت بإیقاف استخدام میتوجیكت<br />إذا توقفت عن استخدام میتوجیكت، تحدث مع طبیبك فورا.<br />إذا كان لدیك إنطباعا بأن تأثیر میتوجیكت شدید جدا أو ضعیف جدا یجب علیك التحدث مع طبیبك أو مع الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما ھو الحال مع كافة الأدویة الأخرى، یمكن أن یسبب ھذا الدواء آثارا جانبیة ولكن لیس بالضرورة أن یصاب بھا كل من<br />یستعملھ. إن كلا من تكرار حدوث الآثار الجانبیة ودرجة خطورتھا یعتمد على حجم الجرعة وعدد مرات تناولھا. وحیث<br />أنھ من الممكن حدوث آثار جانبیة شدیدة حتى مع استعمال جرعة منخفضة فإنھ من المھم أن یقوم طبیبك بمراقبتك بانتظام.<br />سوف یقوم طبیبك باجراء اختبارات للتحقق من التشوھات النامیة في الدم (مثل انخفاض خلایا الدم البیضاء وانخفاض<br />الصفائح الدمویة وتضخم الغدد اللیمفاویة) والتغیرات في الكلى والكبد.<br />أخبر طبیبك فورا إذا كنت تواجھ أي من الأعراض التالیة، لأن ھذا قد یشیر إلى وجود آثار جانبیة خطیرة من الممكن أن<br />تھدد الحیاة، والتي تتطلب معالجة عاجلة ومحددة:<br />&bull; سعال جاف ومستمر وبدون بلغم، ضیق في التنفس، وحمى، وقد تكون ھذه علامات لالتھاب الرئتین [شائع]<br />&bull; بصق أو سعال الدم قد تكون ھذه علامات لنزیف من الرئتین [غیر معروف]<br />&bull; أعراض ناتجة عن تلف الكبد مثل اصفرار الجلد وبیاض العینین؛ فقد یؤدي میثوتریكسیت إلى حدوث تلف كبدي<br />مزمن (تلیف الكبد)، وتكون النسیج الندبي في الكبد (تلیف كبدي)، تحلل الدھون في الكبد [وجمیعھا غیر شائعة]،<br />التھاب الكبد (التھاب كبدي حاد) [نادرة] وفشل كبدي [ نادرة جد ا]ً.<br />&bull; أعراض الحساسیة مثل ظھور طفح جلدي بما في ذلك احمرار جلدي مصحوب بحكة، تورم الیدین، القدمین،<br />الكاحلین، الوجھ، الشفتین، الفم أو الحلق (والتي قد تسبب صعوبة في البلع أو التنفس) والشعور بأنھ سوف یغُمى<br />علیك؛ قد تكون ھذه علامات لتفاعلات تحسسیة شدیدة أو صدمة استھدافیة [نادرة].<br />&bull; أعراض ناتجة عن تلف الكلى مثل تورم الیدین، الكاحلین أو الأقدام أو تغیرات في عدد مرات التبول أو نقص كمیة<br />البول (قلة البول)أو عدم وجود البول (انقطاع البول) ؛ قد تكون ھذه علامات للفشل الكلوي [نادرة].<br />&bull; أعراض العدوى، مثل الحمى، الرعشة، الآلام، واحتقان الحلق؛ وقد یؤدي تناول المیثوتریكسیت أن تصبح أكثر<br />عرضة للإصابة بالعدوى. من الممكن حدوث عدوى شدیدة مثل نوع معین من النیمونیا (النیمونیا التي تسببھا بكتیریا<br />نیموسیستس جیروفیسي ) أو حدوث تسمم في الدم (إنتان الدم) [نادرة].<br />&bull; أعراضمثل ضعف الحركة في إحدى جانبي الجسم (جلطة دماغیة) أو ألم، وتورم، واحمرار، والشعور بدفء غیر<br />عادي في إحدى الساقین (الخثار الوریدي العمیق). قد یحدث ھذا عندما تتسبب الجلطة الدمویة المنزاحة في انسداد<br />أحد الأوعیة الدمویة (الانصمام الخثاري) [نادر]<br />&bull; حمى وتدھور خطیر في الحالة الصحیة العامة، أو حمى مفاجئة مصحوبة باحتقان الحلق أو الفم، أو مشاكل في<br />التبول؛ ویمكن أن یؤدي میثوتریكسیت إلى انخفاض حاد في تعداد خلایا الدم البیضاء (نقص الكریات المحببة) وتثبیط<br />خلایا نخاع العظم بصورة شدیدة [نادرة جد ا]ً.</p><p>&bull; نزیف مفاجئ، مثل نزیف اللثة، ظھور دم في البول، قيء دموي أو كدمات، قد تكون ھذه علامات لانخفاض شدید في<br />الصفائح الدمویة والتي تحدث بسبب تثبیط حاد للخلایا النخاعیة العظمیة [ نادرة جد اً]<br />&bull; قد تشیر أعراضمثل الصداع الحاد في كثیر من الأحیان بالاشتراك مع الحمى وتصلب الرقبة والشعور بالمرض<br />والقيء والارتباك والحساسیة للضوء إلى حدوث التھاب في أغشیة الدماغ (التھاب السحایا العقیم الحاد) [نادرة جدا]<br />&bull; تم الإبلاغ عن اضطرابات الدماغ المعینة (اعتلال الدماغ / اعتلال بیضاء الدماغ) في مرضى السرطان الذین یتلقون<br />المیثوتریكسیت. لا یمكن استبعاد ھذه الآثار الجانبیة عند استخدام العلاج بالمیثوتریكسیت لعلاج الأمراضالأخرى.<br />علامات ھذا النوع من اضطرابات الدماغ قد تغییر في الحالة العقلیة، واضطرابات الحركة (ترنح)، واضطرابات<br />بصریة أو اضطرابات في الذاكرة [غیر معروف]<br />&bull; طفح جلدي شدید أو تقرحات جلدیة (قد یظھر أیضا في الفم، العینین والأعضاء التناسلیة تسمى متلازمة ستیفنز-<br />جونسون أو متلازمة البشرة المحروقة (انحلال البشرة السمي المتنخر) [نادرة جد ا]ً.<br />فیما یلي الرجاء معرفة الآثار الجانبیة الأخرى التي قد تحدث:<br />شائعة جدا: قد تصیب أكثر من ۱ من كل ۱۰ أشخاص<br />&bull; التھاب بطانة الفم ،عسر ھضم ،(الشعور بالاعیاء) ،نقص شھیة الطعام وألم بالبطن.<br />البیلیروبین ، الفوسفاتیز القلوي) . ،ALAT ،ASAT) &bull; نتائج غیرطبیعیة لاختباروظائف الكبد<br />شائعة: قد تصیب حتى ۱ من كل ۱۰ أشخاص<br />&bull; قرح الفم، الإسھال.<br />&bull; الطفح الجلدي، إحمرار الجلد، الحكة.<br />&bull; الصداع، الشعور بالتعب، الدوخة.<br />&bull; نقص في تكوین خلایا الدم مع انخفاض كریات الدم البیضاء أو الحمراء أو الصفائح الدمویة أو كل منھم<br />غیر شائعة الحدوث: قد تصیب حتى ۱ من كل ۱۰۰ شخص<br />&bull; التھاب الحلق<br />&bull; التھاب الأمعاء، والتقیؤ، والتھاب البنكریاس، براز أسود أو تاري، وقرحة الجھاز الھضمي والنزیف<br />&bull; زیادة الحساسیة للضوء، فقدان الشعر،زیادة في عدد العقیدات الروماتیزمیة ،تقرحات الجلد ،الھربس النطاقي ،التھاب<br />الأوعیة الدمویة ،الطفح الجلدي الشبیھ بالھربس ،الشرى (طفح جلدي على ھیئة بثور تسبب حكة).<br />&bull; ظھورأعراض داء البول السكري.<br />&bull; الدوخة، الارتباك، الإكتئاب.<br />&bull; نقص مصل الألبومین.<br />&bull; انخفاض كامل في أعداد خلایا الدم والصفائح الدمویة.<br />&bull; التھابات وقرح في المثانة أو المھبل، انخفاض في أداء الكلیة، إضطراب التبول.<br />&bull; آلام في المفاصل، آلام في العضلات، انخفاض في كتلة العظام.<br />نادرة الحدوث: قد تصیب حتى ۱ من كل ۱٫۰۰۰ شخص<br />&bull; التھاب أنسجة اللثة<br />&bull; زیادة تلون البشرة ، حب الشباب، بقع زرقاء في الجلد ناتجة عن نزیف الأوعیة الدمویة، (كدمات، نمشات) التھاب<br />تحسسي باللأوعیة الدمویة.<br />&bull; انخفاضعدد الأجسام المضادة في الدم.<br />&bull; العدوى (بما في ذلك إعادة تنشیط العدوى المزمنة غیر النشطة)، العین الحمراء (التھاب الملتحمة).<br />&bull; تقلب المزاج (تعدیلات المزاج).<br />&bull; إضطرابات في الرؤیة.<br />&bull; التھاب تحسسى باللأوعیة الدمویة، الحمى، إحمرار العینین، العدوى، تأخر إلتئام الجروح، نقص عدد الأجسام<br />المضادة في الدم.</p><p>&bull; التھاب الكیس حول القلب، تجمع سوائل بالكیس حول القلب وانسداد حشو القلب بسبب وجود سائل في الكیس حول<br />القلب.<br />&bull; انخفاض ضغط الدم.<br />&bull; تشكل نسیج ندبي في الرئة ، تلیف الرئة ، ضیق التنفس والربو القصبي ، تراكم السوائل في الكیس حول الرئة.<br />&bull; كسر الاجھاد.<br />&bull; إضطرابات الالكترولیتات.<br />&bull; الحمى وتأخر التئام الجروح.<br />نادرة الحدوث جدا:ً قد تصیب حتى ۱ من كل ۱۰٫۰۰۰ شخص<br />&bull; التوسع السمي الحاد في القناة الھضمیة (تضخم القولون السمي).<br />&bull; زیادة تصبغات الأظافر، التھاب الجلد (الداحس الحاد) ، التھاب عمیق في بصیلات الشعر(الدمامل)،تضخم واضح<br />للأوعیة الدمویة الصغیرة.<br />&bull; ألم، فقدان القوة أو شعور بالخدر أو التنمیل وجود حساسیة أقل للتحفیز من المعتاد ، تغیر في الطعم في الفم. (إحساس<br />بطعم معدني)، إختلاجات، شلل و التھاب السحایا .<br />&bull; اضطراب الرؤیة غیر الالتھابي (اعتلال الشبكیة)<br />&bull; انخفاض في الرغبة الجنسیة، عجز جنسي، تضخم الثدي لدى الذكور، تشوه الحیوانات المنویة (قلة النطاف )،<br />إضطراب الدورة الشھریة، إفرازات مھبلیة.<br />&bull; تضخم الغدد اللیمفاویة (اللیمفوما).<br />&bull; اضطرابات التكاثر اللمفاوي (النمو المفرط لخلایا الدم البیضاء).<br />غیر معروفة: لا یمكن تقدیر تكرار حدوثھا من البیانات المتاحة:<br />&bull; زیادة عدد خلایا الدم البیضاء.<br />&bull; نزیف الأنف.<br />&bull; البروتینات في البول.<br />&bull; الشعور بالضعف.<br />&bull; تلف عظم الفك ( نمو ثانوي الى مفرط لخلایا الدم البیضاء).<br />&bull; تدمر الأنسجة في موقع الحقن<br />&bull; احمرار وتساقط الجلد<br />&bull; التورم</p><p>إن اعطاء المیثوتریكسیت عن طریق الحقن تحت الجلد جید التحمل. فقط تم ملاحظة حدوث بعض ردود الفعل الخفیفة<br />بالجلد والتي تقل مع استمرار العلاج.<br />الإبلاغ عن الآثار الجانبیة<br />إذا أصابك أي من الآثار الجانبیة، تحدث إلى طبیبك أو الصیدلي. بما في ذلك أي آثار جانبیة محتملة وغیر مدرجة في ھذه<br />النشرة. یمكنك أیضا الإبلاغ عن الآثار الجانبیة مباشرة عبر (انظر التفاصیل أدناه). وبالإبلاغ عن الآثار الجانبیة یمكن أن<br />تساعد في توفیر المزید من المعلومات حول سلامة ھذا الدواء.<br />المركز الوطني للیقظة والسلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲<br />-۲۳٥۳-۲۳٥٦- ۹٦٦ +، تحویلة: ۲۳۱۷ -۱۱- للإتصال بالمركز الوطني للیقظة والسلامة الدوائیة، ھاتف: ۲۰۳۸۲۲۲<br />۲۳٤۰-۲۳۳٤<br />الھاتف المجاني: ۸۰۰۲٤۹۰۰۰۰</p><p>npc.drug@sfda.gov.sa : البرید الاكتروني</p><p>www.sfda.gov.sa/npc :</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ ھذا الدواء بعیدا عن نظر ومتناول الأطفال.<br />یحفظ في درجة حرارة أقل من ۲٥ مئویة.<br />احفظ السرنجة المعبأة مسبق ا دًاخل الكرتونة الخارجیة وذلك لحمایتھا من الضوء.<br />لا تستعمل ھذا الدواء بعد تاریخ إنتھاء الصلاحیة المذكور على العلبة. ویشیر تاریخ إنتھاء الصلاحیة إلى الیوم الأخیر من<br />الشھر المذكور.<br />یجب ألا تتخلص من ھذا الدواء في میاه الصرف ولا في سلة القمامة المنزلیة. إسأل الصیدلي عن كیفیة التخلص من<br />الأدویة التي لم تعد في حاجة إلیھا، ھذه الإجراءات تساعد على حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا یحتوي میتوجیكت<br />&bull; المادة الفعالة ھي میثوتریكسیت. ۱ مللي من المحلول یحتوي على میثوتریكسیت داي صودیوم بما یكافئ ٥۰ مجم<br />میثوتریكسیت.<br />&bull; المواد الأخرى الموجودة في الدواء (المسوغات) ھي كلورید الصودیوم، ھیدروكسید الصودیوم، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كیف یبدو میتوجیكت وما ھي محتویات العبوة؟<br />سرنجات میتوجیكت المعبأة مسبقاً تحتوي على محلول شفاف لونھ بني مائل للاصفرار.<br />العبوات التالیة متوفرة:<br />سرنجات معبأة مسبقا مزودة بإبرة للحقن تحت الجلد وتدریج تحتوي على ۰٫۲۰ مللي، ۰٫۳۰ مللي، ۰٫٤۰ مللي، ۰٫٥۰<br />مللي، ۰٫٦۰ مللي محلول للحقن داخل عبوات تحتوي على سرنجة واحدة معبأة مسبقاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة المالكة لحق التسویق و المصرحة للمستحضر النھائي<br />میداك جیسیلشافت فیر كلینیشیھ شبیسیالبریباراتیھ إم بي إتش<br />ثیاتر شتراسھ ٦<br />۲۲۸۸۰ فیدیل<br />ألمانیا<br />+٤۹٤۱۰۳۸۰۰٦ - ھاتف : ۰<br />+٤۹٤۱۰۳۸۰۰٦ - فاكس : ۱۰۰<br />الشركة المنتجة للمستحضر الدوائي والمسؤولة عن اختبارات رقابة الجودة<br />أنكوتك فارما برودكشن چي. إم. بي . إتش<br />أ م فارما بارك<br />۰٦۸٦۱ دساو- روسلاو<br />ألمانیا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Metoject 50 mg/ml solution for injection, pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml of solution contains 50 mg methotrexate (as methotrexate disodium).
1 pre-filled syringe of 0.20 ml contains 10 mg methotrexate.
1 pre-filled syringe of 0.30 ml contains 15 mg methotrexate.
1 pre-filled syringe of 0.40 ml contains 20 mg methotrexate.
1 pre-filled syringe of 0.50 ml contains 25 mg methotrexate.
1 pre-filled syringe of 0.60 ml contains 30 mg methotrexate
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection, pre-filled syringe.
Clear, yellow-brown solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metoject is indicated for the treatment of<br /> active rheumatoid arthritis in adult patients,<br /> polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal<br />anti-inflammatory drugs (NSAIDs) has been inadequate,<br /> severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy<br />such as phototherapy, PUVA, and retinoids, and severe psoriatic arthritis in adult patients.<br /> mild to moderate Crohn&rsquo;s disease either alone or in combination with corticosteroids in adult patients<br />refractory or intolerant to thiopurines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Important warning about the dosage of Metoject (methotrexate)<br />In the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis and psoriatic arthritis, and<br />Crohn&rsquo;s disease, Metoject (methotrexate) must only be used once a week. Dosage errors in the use of<br />Metoject (methotrexate) can result in serious adverse reactions, including death. Please read this section</p><p>Metoject should only be prescribed by physicians, who are familiar with the various characteristics of the<br />medicinal product and its mode of action. The administration should routinely be done by health<br />professionals. If the clinical situation permits the treating physician can, in selected cases, delegate the<br />subcutaneous administration to the patient her/himself. Patients must be educated and trained in the<br />proper injection technique when self-administering methotrexate. The first injection of Metoject should<br />be performed under direct medical supervision. Metoject is injected subcutaneously once weekly.<br />The patient is to be explicitly informed about the fact of administration once weekly. It is advisable to<br />determine a fixed, appropriate weekday as day of injection.<br />Methotrexate elimination is reduced in patients with a third distribution space (ascites, pleural effusions).<br />Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some<br />cases, discontinuation of methotrexate administration (see section 5.2 and 4.4).<br />Dosage in adult patients with rheumatoid arthritis:<br />The recommended initial dose is 7.5 mg of methotrexate once weekly, administered subcutaneously.<br />Depending on the individual activity of the disease and tolerability by the patient, the initial dose may be<br />increased gradually by 2.5 mg per week. A weekly dose of 25 mg should in general not be exceeded.<br />However, doses exceeding 20 mg/week are associated with significant increase in toxicity, especially<br />bone marrow suppression. Response to treatment can be expected after approximately 4 &ndash; 8 weeks. Upon<br />achieving the therapeutically desired result, the dose should be reduced gradually to the lowest possible<br />effective maintenance dose.<br />Dosage in children and adolescents below 16 years with polyarthritic forms of juvenile idiopathic arthritis<br />The recommended dose is 10-15 mg/m&sup2; body surface area (BSA)/once weekly, administered by<br />subcutaneous injection. In therapy-refractory cases the weekly dosage may be increased up to 20mg/m2<br />body surface area/once weekly. However, an increased monitoring frequency is indicated if the dose is<br />increased.<br />Patients with JIA should always be referred to a rheumatology specialist in the treatment of<br />children/adolescents.<br />Use in children &lt; 3 years of age is not recommended as insufficient data on efficacy and safety is<br />available for this population (see section 4.4).<br />Dosage in patients with psoriasis vulgaris and psoriatic arthritis:<br />It is recommended that a test dose of 5 &ndash; 10 mg should be administered parenterally, one week prior to<br />therapy to detect idiosyncratic adverse reactions. The recommended initial dose is 7.5 mg of methotrexate<br />once weekly, administered subcutaneously. The dose is to be increased gradually but should not, in<br />general, exceed a weekly dose of 25 mg of methotrexate. Doses exceeding 20 mg per week can be<br />associated with significant increase in toxicity, especially bone marrow suppression. Response to<br />treatment can generally be expected after approximately 2 &ndash; 6 weeks. Upon achieving the therapeutically<br />desired result, the dose should be reduced gradually to the lowest possible effective maintenance dose.<br />Dosage in patients with Crohn&rsquo;s disease<br /> Induction treatment:<br />25 mg/week administered subcutaneously.<br />Response to treatment can be expected after approximately 8 to 12 weeks.<br /> Maintenance treatment:<br />15 mg/week administered subcutaneously.</p><p>There is not sufficient experience in the paediatric population to recommend Metoject for the treatment of<br />Crohn&rsquo;s disease in this population.<br />Maximum weekly dose<br />The dose should be increased as necessary but should in general not exceed the maximum recommended<br />weekly dose of 25 mg. In a few exceptional cases a higher dose might be clinically justified, but should<br />not exceed a maximum weekly dose of 30 mg of methotrexate as toxicity will markedly increase.<br />Patients with renal impairment:<br />Metoject should be used with caution in patients with impaired renal function. The dose should be<br />adjusted as follows:<br />Creatinine clearance (ml/min) Dose<br />&gt; 60 100 %<br />30 &ndash; 59 50 %<br />&lt; 30 Metoject must not be used<br />See section 4.3.<br />Patients with hepatic impairment:<br />Methotrexate should be administered with great caution, if at all, to patients with significant current or<br />previous liver disease, especially if due to alcohol. If bilirubin is  5 mg/dl (85.5 &mu;mol/l), methotrexate is<br />contraindicated.<br />For a full list of contraindications, see section 4.3.<br />Use in elderly patients:<br />Dose reduction should be considered in elderly patients due to reduced liver and kidney function as well<br />as lower folate reserves which occur with increased age.<br />Use in patient with a third distribution space (pleural effusions, ascitis):<br />As the half-life of methotrexate can be prolonged to 4 times the normal length in patients who possess a<br />third distribution space dose reduction or, in some cases, discontinuation of methotrexate administration<br />may be required (see section 5.2 and 4.4).<br />Method of administration:<br />The medicinal product is for single use only.<br />Metoject is given by the subcutaneous route in children and adults. See section 6.6 for instructions for<br />subcutaneous use.<br />The overall duration of the treatment is decided by the physician.<br />Note:<br />If changing the oral application to parenteral administration a reduction of the dose may be required due<br />to the variable bioavailability of methotrexate after oral administration.<br />Folic acid supplementation may be considered according to current treatment guidelines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Metoject is contraindicated in the case of 
 hypersensitivity to the active substance or to any of the excipients listed in section 6.1,
 severe liver impairment (see section 4.2),
 alcohol abuse,
 severe renal impairment (creatinine clearance less than 30 ml/min., see section 4.2 and section 4.4),
 pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or
significant anaemia,
 serious, acute or chronic infections such as tuberculosis, HIV or other immunodeficiency syndromes,
 ulcers of the oral cavity and known active gastrointestinal ulcer disease,
 pregnancy, breast-feeding (see section 4.6),
 concurrent vaccination with live vaccines.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients must be clearly informed that the therapy has to be administered once a week, not every day.<br />Patients undergoing therapy should be subject to appropriate supervision so that signs of possible toxic<br />effects or adverse reactions may be detected and evaluated with minimal delay. Therefore methotrexate<br />should be only administered by, or under the supervision of physicians whose knowledge and experience<br />includes the use of antimetabolite therapy. Because of the possibility of severe or even fatal toxic<br />reactions, the patient should be fully informed by the physician of the risks involved and the<br />recommended safety measures.</p><p>Before beginning or reinstituting methotrexate therapy after a rest period:<br />Complete blood count with differential blood count and platelets, liver enzymes, bilirubin, serum<br />albumin, chest x-ray and renal function tests. If clinically indicated, exclude tuberculosis and hepatitis.<br />During therapy (at least once a month during the first six months and every three months thereafter):<br />An increased monitoring frequency should be considered also when the dose is increased.<br />1. Examination of the mouth and throat for mucosal changes<br />2. Complete blood count with differential blood count and platelets. Haemopoietic suppression caused<br />by methotrexate may occur abruptly and with apparently safe dosages. Any profound drop in whitecell<br />or platelet counts indicates immediate withdrawal of the medicinal product and appropriate<br />supportive therapy. Patients should be advised to report all signs and symptoms suggestive of<br />infection. Patients taking simultaneous administration of haematotoxic medicinal products (e.g.<br />leflunomide) should be monitored closely with blood count and platelets.<br />3. Liver function tests: Particular attention should be given to the appearance of liver toxicity.<br />Treatment should not be instituted or should be discontinued if any abnormality of liver function<br />tests, or liver biopsy, is present or develops during therapy. Such abnormalities should return to<br />normal within two weeks after which treatment may be recommenced at the discretion of the<br />physician. There is no evidence to support use of a liver biopsy to monitor hepatic toxicity in<br />rheumatological indications.<br />For psoriasis patients the need of a liver biopsy prior to and during therapy is controversial. Further<br />research is needed to establish whether serial liver chemistry tests or propeptide of type III collagen</p><p>can detect hepatotoxicity sufficiently. The evaluation should be performed case by case and<br />differentiate between patients with no risk factors and patients with risk factors such as excessive<br />prior alcohol consumption, persistent elevation of liver enzymes, history of liver disease, family<br />history of inheritable liver disease, diabetes mellitus, obesity, and history of significant exposure to<br />hepatotoxic drugs or chemicals and prolonged Methotrexate treatment or cumulative doses of 1.5 g<br />or more.<br />Check of liver-related enzymes in serum: Temporary increases in transaminases to twice or three<br />times of the upper limit of normal have been reported by patients at a frequency of 13 &ndash; 20 %. In the<br />case of a constant increase in liver-related enzymes, a reduction of the dose or discontinuation of<br />therapy should be taken into consideration.<br />Due to its potentially toxic effect on the liver, additional hepatotoxic medicinal products should not<br />be taken during treatment with methotrexate unless clearly necessary and the consumption of alcohol<br />should be avoided or greatly reduced (see section 4.5). Closer monitoring of liver enzymes should be<br />exercised in patients taking other hepatotoxic medicinal products concomitantly (e.g. leflunomide).<br />The same should be taken into account with the simultaneous administration of haematotoxic<br />medicinal products (e.g. leflunomide).</p><p>4. Renal function should be monitored by renal function tests and urinanalysis (see sections 4.2<br />and 4.3).<br />As methotrexate is eliminated mainly by renal route, increased serum concentrations are to be<br />expected in the case of renal impairment, which may result in severe undesirable effects.<br />Where renal function may be compromised (e.g. in the elderly), monitoring should take place more<br />frequently. This applies in particular, when medicinal products are administered concomitantly, that<br />affect the elimination of methotrexate, cause kidney damage (e.g. non-steroidal anti-inflammatory<br />medicinal products) or that can potentially lead to impairment of blood formation. Dehydration may<br />also intensify the toxicity of methotrexate.<br />5. Assessment of respiratory system: Alertness for symptoms of lung function impairment and, if<br />necessary lung function test. Pulmonary affection requires a quick diagnosis and discontinuation of<br />methotrexate. Pulmonary symptoms (especially a dry, non-productive cough) or a non-specific<br />pneumonitis occurring during methotrexate therapy may be indicative of a potentially dangerous<br />lesion and require interruption of treatment and careful investigation. Acute or chronic interstitial<br />pneumonitis, often associated with blood eosinophilia, may occur and deaths have been reported.<br />Although clinically variable, the typical patient with methotrexate-induced lung disease presents<br />with fever, cough, dyspnoea, hypoxemia, and an infiltrate on chest X-ray, infection needs to be<br />excluded. Pulmonary affection requires a quick diagnosis and discontinuation of methotrexate<br />therapy. This lesion can occur at all doses. In addition, pulmonary alveolar haemorrhage has been<br />reported with methotrexate used in rheumatologic and related indications. This event may also be<br />associated with vasculitis and other comorbidities. Prompt investigations should be considered when<br />pulmonary alveolar haemorrhage is suspected to confirm the diagnosis.<br />6. Methotrexate may, due to its effect on the immune system, impair the response to vaccination results<br />and affect the result of immunological tests. Particular caution is also needed in the presence of<br />inactive, chronic infections (e.g. herpes zoster, tuberculosis, hepatitis B or C) for reasons of eventual<br />activation. Vaccination using live vaccines must not be carried out under methotrexate therapy.</p><p>Malignant lymphomas may occur in patients receiving low dose methotrexate, in which case therapy must<br />be discontinued. Failure of the lymphoma to show signs of spontaneous regression requires the initiation<br />of cytotoxic therapy.<br />Concomitant administration of folate antagonists such as trimethoprim/sulphamethoxazole has been<br />reported to cause an acute megaloblastic pancytopenia in rare instances.<br />Radiation induced dermatitis and sun-burn can reappear under methotrexate therapy (recall-reaction).<br />Psoriatic lesions can exacerbate during UV-irradiation and simultaneous administration of methotrexate.<br />Methotrexate elimination is reduced in patients with a third distribution space (ascites, pleural effusions).<br />Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some<br />cases, discontinuation of methotrexate administration. Pleural effusions and ascites should be drained<br />prior to initiation of methotrexate treatment (see section 5.2).<br />Diarrhoea and ulcerative stomatitis can be toxic effects and require interruption of therapy, otherwise<br />haemorrhagic enteritis and death from intestinal perforation may occur.<br />Vitamin preparations or other products containing folic acid, folinic acid or their derivatives may decrease<br />the effectiveness of methotrexate.<br />For the treatment of psoriasis, methotrexate should be restricted to severe recalcitrant, disabling psoriasis<br />which is not adequately responsive to other forms of therapy, but only when the diagnosis has been<br />established by biopsy and/or after dermatological consultation.<br />Encephalopathy leukoencephalopathy have been reported in oncologic patients receiving methotrexate<br />therapy and cannot be excluded for methotrexate therapy in non-oncologic indications.</p><p>&nbsp;</p><p>Fertility and reproduction<br />Fertility<br />Methotrexate has been reported to cause oligospermia, menstrual dysfunction and amenorrhoea in<br />humans, during and for a short period after cessation of therapy, and to cause impaired fertility, affecting<br />spermatogenesis and oogenesis during the period of its administration &ndash; effects that appear to be<br />reversible on discontinuing therapy.<br />Teratogenicity &ndash; Reproductive risk<br />Methotrexate causes embryotoxicity, abortion and foetal defects in humans. Therefore, the possible risks<br />of effects on reproduction, pregnancy loss and congenital malformations should be discussed with female<br />patients of childbearing potential (see section 4.6). The absence of pregnancy must be confirmed before<br />Metoject is used. If women of a sexually mature age are treated, effective contraception must be<br />performed during treatment and for at least six months after.<br />For contraception advice for men see section 4.6.<br />Sodium<br />This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially<br />&ldquo;sodium-free&rdquo;.<br />Paediatric population</p><p>Use in children &lt; 3 years of age is not recommended as insufficient data on efficacy and safety are<br />available for this population (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nitrous oxide<br />The use of nitrous oxide potentiates the effect of methotrexate on folate metabolism, yielding increased<br />toxicity such as severe, unpredictable myelosuppression, and stomatitis. Whilst this effect can be reduced<br />by administering calcium folinate, the concomitant use of nitrous oxide and methotrexate should be<br />avoided.<br />Alcohol, hepatotoxic medicinal products, haematotoxic medicinal products<br />The probability of methotrexate exhibiting a hepatotoxic effect is increased by regular alcohol<br />consumption and when other hepatotoxic medicinal products are taken at the same time (see section 4.4).<br />Patients taking other hepatotoxic medicinal products concomitantly (e.g. leflunomide) should be<br />monitored with special care. The same should be taken into account with the simultaneous administration<br />of haematotoxic medicinal products (e.g. leflunomide, azathioprine, retinoids, sulfasalazine). The<br />incidence of pancytopenia and hepatotoxicity can be increased when leflunomide is combined with<br />methotrexate.<br />Combined treatment with methotrexate and retinoids like acitretin or etretinate increases the risk of<br />hepatotoxicity.<br />Oral antibiotics<br />Oral antibiotics like tetracyclines, chloramphenicol, and non-absorbable broad-spectrum antibiotics can<br />interfere with the enterohepatic circulation, by inhibition of the intestinal flora or suppression of the<br />bacterial metabolism.<br />Antibiotics<br />Antibiotics, like penicillines, glycopeptides, sulfonamides, ciprofloxacin and cefalotin can, in individual<br />cases, reduce the renal clearance of methotrexate, so that increased serum concentrations of methotrexate<br />with simultaneous haematological and gastro-intestinal toxicity may occur.<br />Medicinal products with high plasma protein binding<br />Methotrexate is plasma protein bound and may be displaced by other protein bound medicinal products<br />such as salicylates, hypoglycaemics, diuretics, sulphonamides, diphenylhydantoins, tetracyclines,<br />chloramphenicol and p-aminobenzoic acid, and the acidic anti-inflammatory agents, which can lead to<br />increased toxicity when used concurrently.<br />Probenecid, weak organic acids, pyrazoles and non-steroidal anti-inflammatory agents<br />Probenecid, weak organic acids such as loop diuretics, and pyrazoles (phenylbutazone) can reduce the<br />elimination of methotrexate and higher serum concentrations may be assumed inducing higher<br />haematological toxicity. There is also a possibility of increased toxicity when low dose methotrexate and<br />non steroidal anti-inflammatory medicinal products or salicylates are combined.<br />Medicinal products with adverse reactions on the bone marrow<br />In the case of medication with medicinal products which may have adverse reactions on the bone marrow<br />(e.g. sulphonamides, trimethoprim-sulphamethoxazole, chloramphenicol, pyrimethamine); attention<br />should be paid to the possibility of pronounced impairment of blood formation.</p><p>Medicinal products which cause folate deficiency<br />The concomitant administration of products which cause folate deficiency (e.g. sulphonamides,<br />trimethoprim-sulphamethoxazole) can lead to increased methotrexate toxicity. Particular care is therefore<br />advisable in the presence of existing folic acid deficiency.<br />Products containing folic acid or folinic acid<br />Vitamin preparations or other products containing folic acid, folinic acid or their derivatives may decrease<br />the effectiveness of methotrexate.<br />Other antirheumatic medicinal products<br />An increase in the toxic effects of methotrexate is, in general, not to be expected when Metoject is<br />administered simultaneously with other antirheumatic medicinal products (e.g. gold compounds,<br />penicillamine, hydroxychloroquine, sulfasalazine, azathioprin, cyclosporin).<br />Sulfasalazine<br />Although the combination of methotrexate and sulfasalazine can cause an increase in efficacy of<br />methotrexate and as a result more undesirable effects due to the inhibition of folic acid synthesis through<br />sulphasalazine, such undesirable effects have only been observed in rare individual cases in the course of<br />several studies.<br />Mercaptopurine<br />Methotrexate increases the plasma levels of mercaptopurine. The combination of methotrexate and<br />mercaptopurine may therefore require dose adjustment.<br />Proton-pump inhibitors<br />A concomitant administration of proton-pump inhibitors like omeprazole or pantoprazole can lead to<br />interactions: Concomitant administration of methotrexate and omeprazole has led to delayed renal<br />elimination of methotrexate. In combination with pantoprazole inhibited renal elimination of the<br />metabolite 7-hydroxymethotrexate with myalgia and shivering was reported in one case.<br />Theophylline<br />Methotrexate may decrease the clearance of theophylline; theophylline levels should be monitored when<br />used concurrently with methotrexate.<br />Caffeine- or theophylline-containing beverages<br />An excessive consumption of caffeine- or theophylline-containing beverages (coffee, caffeine-containing<br />soft drinks, black tea) should be avoided during methotrexate therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential/Contraception in females<br />Women must not get pregnant during methotrexate therapy, and effective contraception must be used<br />during treatment with methotrexate and at least 6 months thereafter (see section 4.4). Prior to initiating<br />therapy, women of childbearing potential must be informed of the risk of malformations associated with<br />methotrexate and any existing pregnancy must be excluded with certainty by taking appropriate measures,<br />e.g. a pregnancy test. During treatment pregnancy tests should be repeated as clinically required (e.g. after<br />any gap of contraception). Female patients of reproductive potential must be counselled regarding<br />pregnancy prevention and planning.<br />Contraception in males<br />It is not known if methotrexate is present in semen. Methotrexate has been shown to be genotoxic in<br />animal studies, such that the risk of genotoxic effects on sperm cells cannot completely be excluded.<br />Limited clinical evidence does not indicate an increased risk of malformations or miscarriage following<br />paternal exposure to low-dose methotrexate (less than 30 mg/week). For higher doses, there is insufficient<br />data to estimate the risks of malformations or miscarriage following paternal exposure.<br />As precautionary measures, sexually active male patients or their female partners are recommended to use<br />reliable contraception during treatment of the male patient and for at least 6 months after cessation of<br />methotrexate. Men should not donate semen during therapy or for 6 months following discontinuation of<br />methotrexate.<br />Pregnancy<br />Methotrexate is contraindicated during pregnancy in non-oncological indications (see section 4.3). If<br />pregnancy occurs during treatment with methotrexate and up to six months thereafter, medical advice<br />should be given regarding the risk of harmful effects on the child associated with treatment and<br />ultrasonography examinations should be performed to confirm normal foetal development.<br />In animal studies, methotrexate has shown reproductive toxicity, especially during the first trimester (see<br />section 5.3). Methotrexate has been shown to be teratogenic to humans; it has been reported to cause<br />foetal death, miscarriages and/or congenital abnormalities (e.g. craniofacial, cardiovascular, central<br />nervous system and extremity-related).<br />Methotrexate is a powerful human teratogen, with an increased risk of spontaneous abortions, intrauterine<br />growth restriction and congenital malformations in case of exposure during pregnancy.<br />&bull; Spontaneous abortions have been reported in 42.5% of pregnant women exposed to low-dose<br />methotrexate treatment (less than 30 mg/week), compared to a reported rate of 22.5% in disease-matched<br />patients treated with drugs other than methotrexate.<br />&bull; Major birth defects occurred in 6.6% of live births in women exposed to low-dose methotrexate<br />treatment (less than 30 mg/week) during pregnancy, compared to approximately 4% of live births in<br />disease-matched patients treated with drugs other than methotrexate.<br />Insufficient data is available for methotrexate exposure during pregnancy higher than 30 mg/week, but<br />higher rates of spontaneous abortions and congenital malformations are expected.<br />When methotrexate was discontinued prior to conception, normal pregnancies have been reported.<br />Breast-feeding<br />Methotrexate is excreted in human milk. Because of the potential for serious adverse reactions in breastfed<br />infants, Metoject is contraindicated during breast-feeding (see section 4.3). Therefore breast-feeding<br />must be discontinued prior to and throughout administration.<br />Fertility<br />Methotrexate affects spermatogenesis and oogenesis and may decrease fertility. In humans, methotrexate<br />has been reported to cause oligospermia, menstrual dysfunction and amenorrhoea. These effects appear to<br />be reversible after discontinuation of therapy in most cases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Central nervous symptoms such as tiredness and dizziness can occur during treatment, Metoject has<br />minor or moderate influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Most serious adverse reactions of methotrexate include bone marrow suppression, pulmonary toxicity,<br />hepatotoxicity, renal toxicity, neurotoxicity, thromboembolic events, anaphylactic shock and Stevens-<br />Johnson syndrome.<br />Most frequently (very common) observed adverse reactions of methotrexate include gastrointestinal<br />disorders e.g. stomatitis, dyspepsia, abdominal pain, nausea, loss of appetite and abnormal liver function<br />tests e.g. increased ALAT, ASAT, bilirubin, alkaline phosphatase. Other frequently (common) occurring<br />adverse reactions are leukopenia, anaemia, thrombopenia, headache, tiredness, drowsiness, pneumonia,<br />interstitial alveolitis/pneumonitis often associated with eosinophilia, oral ulcers, diarrhoea, exanthema,<br />erythema and pruritus.<br />Tabulated list of adverse reactions<br />The most relevant undesirable effects are suppression of the haematopoietic system and gastrointestinal<br />disorders.<br />The following headings are used to organise the undesirable effects in order of frequency:<br />Very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000<br />to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data)<br />Infections and infestations<br />Uncommon: Pharyngitis.<br />Rare: Infection (incl. reactivation of inactive chronic infection), sepsis, conjunctivitis.<br />Neoplasms benign, malignant and unspecified (including cysts and polyps)<br />Very rare: Lymphoma (see &ldquo;description&rdquo; below).<br />Blood and lymphatic system disorders<br />Common: Leukopenia, anaemia, thrombopenia.<br />Uncommon: Pancytopenia.<br />Very rare: Agranulocytosis, severe courses of bone marrow depression , lymphoproliferative disorders<br />(see &ldquo;description&rdquo; below).<br />Not known: Eosinophilia.<br />Immune system disorders<br />Rare: Allergic reactions, anaphylactic shock, hypogammaglobulinaemia.<br />Metabolism and nutrition disorders<br />Uncommon: Precipitation of diabetes mellitus.<br />Psychiatric disorders<br />Uncommon: Depression, confusion.</p><p>Rare: Mood alterations.<br />Nervous system disorders<br />Common: Headache, tiredness, drowsiness.<br />Uncommon: Dizziness<br />Very rare: Pain, muscular asthenia or paraesthesia/hypoaesthesia, changes in sense of taste (metallic<br />taste), convulsions, meningism, acute aseptic meningitis, paralysis.<br />Not known: Encephalopathy/ leukoencephalopathy.<br />Eye disorders<br />Rare: Visual disturbances.<br />Very rare: Impaired vision, retinopathy.<br />Cardiac disorders<br />Rare: Pericarditis, pericardial effusion, pericardial tamponade.<br />Vascular disorders<br />Rare: Hypotension, thromboembolic events.<br />Respiratory, thoracic and mediastinal disorders<br />Common: Pneumonia, interstitial alveolitis/pneumonitis often associated with eosinophilia. Symptoms<br />indicating potentially severe lung injury (interstitial pneumonitis) are: dry, not productive cough, short of<br />breath and fever.<br />Rare: Pulmonary fibrosis, Pneumocystis jirovecii pneumonia, shortness of breath and bronchial asthma,<br />pleural effusion.<br />Not known: Epistaxis, pulmonary alveolar haemorrhage.<br />Gastrointestinal disorders<br />Very common: Stomatitis, dyspepsia, nausea, loss of appetite, abdominal pain.<br />Common: Oral ulcers, diarrhoea.<br />Uncommon: Gastrointestinal ulcers and bleeding, enteritis, vomiting, pancreatitis.<br />Rare: Gingivitis.<br />Very rare: Haematemesis, haematorrhea, toxic megacolon.<br />Hepatobiliary disorders (see section 4.4)<br />Very common: Abnormal liver function tests (increased ALAT, ASAT, alkaline phosphatase and<br />bilirubin).<br />Uncommon: Cirrhosis, fibrosis and fatty degeneration of the liver, decrease in serum albumin.<br />Rare: Acute hepatitis.<br />Very rare: Hepatic failure.<br />Skin and subcutaneous tissue disorders<br />Common: Exanthema, erythema, pruritus.<br />Uncommon: Photosensitisation, loss of hair, increase in rheumatic nodules, skin ulcer, herpes zoster,<br />vasculitis, herpetiform eruptions of the skin, urticaria.<br />Rare: Increased pigmentation, acne, petechiae, ecchymosis, allergic vasculitis.<br />Very rare: Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell&rsquo;s syndrome), increased<br />pigmentary changes of the nails, acute paronychia, furunculosis, telangiectasia.<br />Not known: Skin exfoliation/dermatitis exfoliative</p><p>Musculoskeletal and connective tissue disorders<br />Uncommon: Arthralgia, myalgia, osteoporosis.<br />Rare: Stress fracture.<br />Not known: Osteonecrosis of jaw (secondary to lymphoproliferative disorders).<br />Renal and urinary disorders<br />Uncommon: Inflammation and ulceration of the urinary bladder, renal impairment, disturbed micturition.<br />Rare: Renal failure, oliguria, anuria, electrolyte disturbances.<br />Not known: Proteinuria<br />Reproductive system and breast disorders<br />Uncommon: Inflammation and ulceration of the vagina.<br />Very rare: Loss of libido, impotence, gynaecomastia, oligospermia, impaired menstruation, vaginal<br />discharge.<br />General disorders and administration site conditions<br />Rare: Fever, wound-healing impairment<br />Not known: Asthenia, injection site necrosis, oedema.<br />Description of selected adverse reactions<br />The appearance and degree of severity of undesirable effects depends on the dosage level and the<br />frequency of administration. However, as severe undesirable effects can occur even at lower doses, it is<br />indispensable that patients are monitored regularly by the doctor at short intervals.<br />Lymphoma/Lymphoproliferative disorders: there have been reports of individual cases of lymphoma and<br />other lymphoproliferative disorders which subsided in a number of cases once treatment with<br />methotrexate had been discontinued.<br />Subcutaneous application of methotrexate is locally well tolerated. Only mild local skin reactions (such as<br />burning sensations, erythema, swelling, discolouration, pruritus, severe itching, pain) were observed,<br />decreasing during therapy.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows<br />continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are<br />asked to report any suspected adverse reactions via (see details below).<br />The National Pharmacovigilance &amp; Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a) Symptoms of overdose<br />Toxicity of methotrexate mainly affects the haematopoietic system.<br />b) Treatment measures in the case of overdose</p><p>Calcium folinate is the specific antidote for neutralising the toxic undesirable effects of methotrexate.<br />In cases of accidental overdose, a dose of calcium folinate equal to or higher than the offending dose of<br />methotrexate should be administered intravenously or intramuscularly within one hour and dosing<br />continued until the serum levels of methotrexate are below 10-7 mol/l.<br />In cases of massive overdose, hydration and urinary alkalisation may be necessary to prevent precipitation<br />of methotrexate and/or its metabolites in the renal tubules. Neither haemodialysis nor peritoneal dialysis<br />has been shown to improve methotrexate elimination. Effective clearance of methotrexate has been<br />reported with acute, intermittent haemodialysis using a high flux dialyser.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties<br />Pharmacotherapeutic group: Folic acid analogues,<br />ATC code: L01BA01<br />Antirheumatic medicinal product for the treatment of chronic, inflammatory rheumatic diseases and<br />polyarthritic forms of juvenile idiopathic arthritis. Immunomodulating and anti-inflammatory agent for<br />the treatment of Crohn&rsquo;s disease.<br />Mechanism of action<br />Methotrexate is a folic acid antagonist which belongs to the class of cytotoxic agents known as<br />antimetabolites. It acts by the competitive inhibition of the enzyme dihydrofolate reductase and thus<br />inhibits DNA synthesis. It has not yet been clarified, as to whether the efficacy of methotrexate, in the<br />management of psoriasis, psoriasis arthritis and chronic polyarthritis, is due to an anti-inflammatory or<br />immunosuppressive effect and to which extent a methotrexate-induced increase in extracellular adenosine<br />concentration at inflamed sites contributes to these effects.<br />International clinical guidelines reflect the use of methotrexate as a second choice for Crohn&rsquo;s disease<br />patients that are intolerant or have failed to respond to first-line immunomodulating agents as<br />azathioprine (AZA) or 6-mercaptopurine (6 MP).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Following oral administration, methotrexate is absorbed from the gastrointestinal tract. In case of lowdosed<br />administration (dosages between 7.5 mg/m&sup2; and 80 mg/m&sup2; body surface area), the mean<br />bioavailability is approx. 70 %, but considerable interindividual and intraindividual deviations are<br />possible (25 &ndash; 100 %). Maximum serum concentrations are achieved after 1 &ndash; 2 hours.<br />Bioavailability of subcutaneous injection is nearly 100 %.<br />Distribution<br />Approximately 50 % of methotrexate is bound to serum proteins. Upon being distributed into body<br />tissues, high concentrations in the form of polyglutamates are found in the liver, kidneys and spleen in<br />particular, which can be retained for weeks or months. When administered in small doses, methotrexate<br />passes into the cerebrospinal fluid in minimal amounts. The terminal half-life is on average 6 &ndash; 7 hours<br />and demonstrates considerable variation (3 &ndash; 17 hours). The half-life can be prolonged to 4 times the<br />normal length in patients who possess a third distribution space (pleural effusion, ascites).</p><p>Biotransformation<br />Approx. 10 % of the administered methotrexate dose is metabolised intrahepatically. The principle<br />metabolite is 7-hydroxymethotrexate.<br />Elimination<br />Excretion takes places, mainly in unchanged form, primarily renal via glomerular filtration and active<br />secretion in the proximal tubulus.<br />Approx. 5 &ndash; 20 % methotrexate and 1 &ndash; 5 % 7-hydroxymethotrexate are eliminated biliary. There is<br />pronounced enterohepatic circulation.<br />In the case of renal impairment, elimination is delayed significantly. Impaired elimination with regard to<br />hepatic impairment is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies show that methotrexate impairs fertility, is embryo- and foetotoxic and teratogenic.<br />Methotrexate is mutagenic in vivo and in vitro. As conventional carcinogenicity studies have not been<br />performed and data from chronic toxicity studies in rodents are inconsistent, methotrexate is considered<br />not classifiable as to its carcinogenicity to humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride<br />Sodium hydroxide for pH adjustment<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal<br />products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25 &deg;C. Keep the pre-filled syringes in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nature of container:<br />Pre-filled syringes of colourless glass (type I) of 1 ml capacity with embedded injection needle. Plunger<br />stoppers of chlorobutyl rubber (type I) and polystyrene rods inserted on the stopper to form the syringe<br />plunger</p><p>Pack sizes:<br />Pre-filled syringes containing 0.20 ml, 0.30 ml, 0.40 ml, 0.50 ml or 0.60 ml solution are available in<br />packs of 1 syringe with embedded s.c. injection needle.<br />All pack sizes are available with graduation marks.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The manner of handling and disposal must be consistent with that of other cytotoxic preparations in<br />accordance with local requirements. Pregnant health care personnel should not handle and/or administer<br />Metoject.<br />Methotrexate should not come into contact with the skin or mucosa. In the event of contamination, the<br />affected area must be rinsed immediately with ample amount of water.<br />For single use only.<br />Any unused medicinal product or waste should be disposed of in accordance with local requirements.<br />Instructions for subcutaneous use<br />The best places for the injection are:<br />- upper thighs,<br />- abdomen except around the navel.<br />1. Clean the area of and around the chosen injection site.<br />2. Pull the protective plastic cap straight off.<br />3. Build a skin fold by gently squeezing the area at the injection site.<br />4. The fold must be held pinched until the syringe is removed from the skin after the injection.<br />5. Push the needle fully into the skin at a 90-degree angle.<br />6. Push the plunger down slowly and inject the liquid underneath the skin. Remove the syringe from the<br />skin at the same 90-degree angle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                medac
Gesellschaft für klinische Spezialpräparate mbH
Theaterstr. 6
22880 Wedel
Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12.01.2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>